An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will release its financial results for the quarter ending March 31, 2023, post-market on May 8, 2023. A conference call to discuss the results is scheduled for 4:30 PM ET on the same day. Interested participants can join the call by dialing (877) 407-8037 for U.S. participants or (201) 689-8037 for international callers. The event will also be available via live and archived webcast on the Establishment Labs investor relations webpage.
Establishment Labs specializes in medical technology focused on women's health, offering products like the Motiva® breast devices, which are backed by over 200 patents. The company operates two manufacturing facilities in Costa Rica, adhering to strict regulatory standards.
Positive
Establishment Labs is poised to report financial results for Q1 2023, which may highlight growth trends.
The company has delivered over three million Motiva® devices, establishing a strong market presence.
Negative
None.
NEW YORK--(BUSINESS WIRE)--
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2023 after the market closes on Monday, May 8, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results.
To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037 (International) and use conference ID number 13738535. The call will also be available via live or archived webcast on the “Investor Relations” section of the Establishment Labs website at www.establishmentlabs.com.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness through the power of science, engineering, and technology. The Company offers a portfolio of Femtech solutions for breast health, breast aesthetics and breast reconstruction. The over three million Motiva® devices Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have created a new standard for safety and patient satisfaction in the 85 countries in which they are available. The Motiva Flora® tissue expander is the only regulatory-approved expander in the world with an integrated port that is MRI conditional and is used to improve outcomes in breast reconstruction following breast cancer. Mia Femtech™, Establishment Lab’s unique minimally invasive experience for breast harmony, is the Company’s most recent breakthrough innovation. These solutions are supported by over 200 patents and patent applications in 25 separate patent families worldwide and over 50 scientific studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. In 2018, the Company received an investigational device exemption (IDE) from the FDA for Motiva Implants® and began a clinical trial to support regulatory approval in the United States. Please visit our website for additional information at www.establishmentlabs.com.
